GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Total Current Liabilities

ABCL (AbCellera Biologics) Total Current Liabilities : $75.40 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. AbCellera Biologics's total current liabilities for the quarter that ended in Mar. 2025 was $75.40

AbCellera Biologics Total Current Liabilities Historical Data

The historical data trend for AbCellera Biologics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Total Current Liabilities Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial 103.49 120.68 118.32 119.01 76.61

AbCellera Biologics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.88 70.38 79.57 76.61 75.40

AbCellera Biologics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

AbCellera Biologics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=50.812+4.621
+Other Current Liabilities+Current Deferred Liabilities
=0+21.179
=76.61

AbCellera Biologics's Total Current Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=44.762+4.637
+Other Current Liabilities+Current Deferred Liabilities
=0+25.997
=75.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

AbCellera Biologics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Total Current Liabilities
Comparable Companies
QURE RCKT XNCR DAWN LENZ BCAX CMRX IMNM AVXL CVAC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
8QQ:Germany
Address
150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
Website
https://www.abcellera.com
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Executives
Thermopylae Holdings Ltd. 10 percent owner 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
John S. Montalbano director C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault director, officer: Chief Operating Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth officer: Chief Financial Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer director, 10 percent owner PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer officer: Chief Technology Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G. director, 10 percent owner, officer: Chief Executive Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart officer: Chief Legal Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel director 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p. 10 percent owner 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301